Abstract:Non-alcoholic fatty liver disease (NAFLD) is affecting up to one-third of the general population in western countries. While the major cause of NAFLD is related to an unhealthy lifestyle, recent evidence has shown a role of chemical exposure in the induction and progression of NAFLD. Perfluorooctanoate (PFOA) is a ubiquitous environmental contaminant that exerts its hepatotoxicity mainly through the activation of peroxisome proliferator-activated receptor α (PPARα). We examined how PFOA might affect the progression of NAFLD and whether a preexisting fatty liver intensified or alleviated the effects of PFOA in the livers. As such, male C57BL/6 mice were fed with a low-fat control diet (CD) or a high fat diet (HFD) for 16 weeks to model normal or steatotic livers, respectively. Mice were then administered with PFOA (1mg/kg/d) by oral gavage for an additional 2, 8, and 16 weeks. Dietary treatment was continued throughout the whole study. We found HFD induced hepatic steatosis, lobular inflammation, and progressive fibrosis in mice. As expected, PFOA activated PPARα, constitutive androstane receptor (CAR) and pregnane X receptor (PXR), regardless of the diet. Gene expression analysis showed the interactions between HFD and PFOA on hepatic nuclear receptors were time-dependent. Hepatocytes growth as measured by DNA synthesis and cell growth genes induced by PFOA were exacerbated in the HFD group after 2 weeks, along with the enhanced activation of PPARα. In contrast, PFOA decreased the severity of hepatic steatosis. In HFD-fed mice, the hepatic triglyceride levels were reduced to 75%, 47%, and 40%, after 2, 8, and 16 weeks of PFOA treatment, respectively, compared to vehicle controls. Transcriptomic analysis showed the preexisting NAFLD enhanced PFOA related lipid oxidation pathways in mice. HFD induced hepatic fibrosis as measured by collagen staining and fibrosis gene markers were also attenuated by PFOA. Taken together, this study demonstrated that the preexisting NAFLD might impact on many biological effects induced by PFOA and thus need to be carefully considered as a factor in risk assessment.

Modulation Of Ammonium Perfluorooctanoate-Induced Hepatic Damage By Genetically Different Ppar Alpha In Mice

Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARα in mice

Microgram-order Ammonium Perfluorooctanoate May Activate Mouse Peroxisome Proliferator-Activated Receptor Alpha, but Not Human PPARalpha.

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARα.

The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.

Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice

Activation of Peroxisome Proliferator-Activated Receptor Α Ameliorates Perfluorododecanoic Acid-Induced Production of Reactive Oxygen Species in Rat Liver

Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes

Human Peroxisome Proliferator-activated Receptor Α (pparα) Supports the Induction of Peroxisome Proliferation in PPARα-deficient Mouse Liver

Bile Acid Metabolism Disorder Mediates Hepatotoxicity of Nafion By-Product 2 and Perfluorooctane Sulfonate in Male PPARα-KO Mice.

Evaluating the mode of action of perfluorooctanoic acid-induced liver tumors in male Sprague-Dawley rats using a toxicogenomic approach

Activation of sterol regulatory element-binding proteins in mice exposed to perfluorooctanoic acid for 28 days

Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes

Alleviation Of Toxicity Caused By Overactivation Of Ppar Alpha Through Ppar Alpha-Inducible Mir-181a2

Hepatocyte-specific Mas Activation Enhances Lipophagy and Fatty Acid Oxidation to Protect Against Acetaminophen-Induced Hepatotoxicity in Mice

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Activation of PPARαimproves PPARγ-induced fatty liver in the mouse

Comparative Hepatotoxicity of Novel PFOA Alternatives (Perfluoropolyether Carboxylic Acids) on Male Mice.

Molecular Mechanisms of Perfluorooctanoate-Induced Hepatocyte Apoptosis in Mice Using Proteomic Techniques.

High Fat Diet Feeding Exaggerates Perfluorooctanoic Acid-Induced Liver Injury in Mice via Modulating Multiple Metabolic Pathways